Welcome to our dedicated page for Vaccinex news (Ticker: VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex stock.
Vaccinex, Inc. (VCNX) is a clinical-stage biotechnology company headquartered in Rochester, NY. Specializing in the discovery and development of human therapeutic monoclonal antibodies, therapeutic vaccines, and other biologic products, Vaccinex is dedicated to addressing serious diseases with unmet medical needs, including cancer, multiple sclerosis, and other autoimmune diseases.
The company is pioneering a unique approach to treating cancer and neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). Vaccinex's leading drug candidate, pepinemab, is designed to block SEMA4D, a potent agent believed to prevent immune infiltration into tumors and reduce inflammation in chronic brain diseases. Currently, pepinemab is undergoing evaluation in a Phase 1b/2 study for recurrent or metastatic head and neck cancer and in a Phase 1/2a study for Alzheimer’s Disease. Additionally, there is ongoing exploration for potential Phase 3 development in Huntington's disease.
Vaccinex conducts research both in-house and through collaborations with prominent academic institutions and biotechnology firms. The company's proprietary drug discovery platform, ActivMAb, plays a significant role in its innovative drug development approach. The development team at Vaccinex comprises experienced industry veterans skilled in therapeutic biologics research, manufacturing, quality control, toxicology, pharmacology, regulatory affairs, and clinical affairs.
Recently, Vaccinex has achieved notable milestones, including a 1-for-15 reverse stock split to regain compliance with Nasdaq listing standards and the advancement of its clinical trials. The company continues to secure funding for its research, with significant investments from the Alzheimer’s Drug Discovery Foundation and grants from the Alzheimer’s Association.
Vaccinex remains committed to advancing its clinical programs and expanding its pipeline of innovative therapies to improve patient outcomes in challenging diseases.
Vaccinex, Inc. (Nasdaq: VCNX) announced its financial results for Q3 2020, ending with cash and cash equivalents of $17.1 million. While the SIGNAL phase 2 trial for Pepinemab in Huntington's disease did not meet co-primary endpoints, encouraging metrics suggest further development is warranted. The company plans to initiate a Phase 1b/2 trial of Pepinemab with KEYTRUDA for head and neck cancer in H1 2021 and a Phase 1/2 study for Alzheimer's disease in 2021, with partial funding from prominent associations.
Vaccinex, Inc. (Nasdaq: VCNX) announced positive findings from its Phase 2 SIGNAL study of pepinemab in treating Huntington's disease (HD). The data suggests cognitive benefits and reduced brain atrophy in HD patients. CEO Dr. Maurice Zauderer will present the findings at the Huntington Study Group conference from October 29-31, 2020. Key analyses show significant treatment benefits and well-tolerated safety profiles, supporting further development of pepinemab for HD and other neurodegenerative diseases like Alzheimer's.
Vaccinex, Inc. (Nasdaq: VCNX) announced promising results from its Phase 2 SIGNAL trial of pepinemab for Huntington's disease (HD), presented during the Huntington Study Group conference. The data indicate significant cognitive benefits and reduced brain atrophy in HD patients treated with pepinemab. Key findings include strong improvements in the HD-Cognitive Assessment Battery and clinical assessments. The company aims to further develop pepinemab for HD and other neurodegenerative diseases. Safety data show good tolerability and low dropout rates, supporting its potential for combination therapies.
Vaccinex, Inc. (Nasdaq: VCNX) has announced a live moderated video webcast featuring management and KOL Eric Siemers, MD on October 27, 2020, at 10:00 AM EDT. The discussion will cover insights from the SIGNAL phase 2 study in Huntington’s disease, its implications for Alzheimer’s disease, and a review of the combination treatment of pepinemab with Keytruda® for Head & Neck Cancer. The event will be accessible via the Investors section of Vaccinex’s website, with a replay available two hours after the live session.
Vaccinex, Inc. (Nasdaq: VCNX) announced topline results from its Phase 2 SIGNAL trial of pepinemab in Huntington's disease patients. Although the study did not meet its co-primary endpoints, cognitive assessments showed a trend towards improvement. Pepinemab was well-tolerated, with low discontinuation rates. The company plans to initiate a new study for Alzheimer's disease and expects to balance its budget to support ongoing research. The results indicate that patients with greater cognitive deficits may benefit more from pepinemab treatment.
Vaccinex (Nasdaq: VCNX) announced a clinical collaboration with Merck to assess the combination of its SEMA4D inhibitor, pepinemab, and Merck's KEYTRUDA® for treating advanced head and neck squamous cell carcinoma (HNSCC). The study will include a dose escalation phase and an expansion phase with up to 65 patients, focusing on enhancing immunotherapy efficacy. Key endpoints will encompass objective response, progression-free survival, and overall survival. Pepinemab has shown promise in preclinical studies for enhancing immune responses in tumors.
Vaccinex, Inc. (Nasdaq: VCNX) announced the appointment of Robert Scala as Chief Commercial Officer, effective immediately. Scala will oversee all commercial functions and strategic operations for the company, starting with pepinemab, a potential treatment for Huntington’s disease. With over 30 years of experience in neurology, oncology, and immunology, Scala previously held leadership roles at biotechnology firms and major pharmaceutical companies. This appointment signifies a pivotal growth phase for Vaccinex, enhancing its commercial capabilities in addressing the unmet needs in Huntington’s disease.
Vaccinex reported its financial results for Q2 2020, raising $19.8 million in funding since June 30. The company anticipates topline data from its SIGNAL trial for Huntington's disease by early October 2020. A Phase 1/2 trial for pepinemab in Alzheimer’s is expected to begin enrolling patients in September. R&D expenses decreased to $4.6 million from $7.3 million in 2019, while general and administrative expenses increased to $1.9 million. Cash and equivalents fell to $0.5 million from $2.8 million at year-end 2019.
Vaccinex, Inc. (VCNX) remains on schedule to complete its pivotal SIGNAL trial for Huntington's disease despite COVID-19 challenges. The trial includes 265 subjects, with data collection almost complete; only two subjects are pending due to pandemic delays. Database lock is expected by September, with topline results anticipated in October. The FDA has approved primary and secondary endpoints for the trial, and initial results show potential cognitive improvements linked to pepinemab treatment. The company aims to advance therapies for Huntington’s and other neurodegenerative diseases.
Vaccinex, a clinical-stage biotechnology firm, will host a Virtual Investor Fireside Chat featuring CEO Maurice Zauderer, Ph.D., on June 16, 2020, at 10:00 AM ET. The event will include a live webcast and an interactive Q&A session for attendees. Vaccinex focuses on developing antibody therapies for Huntington's disease and cancer, with ongoing clinical trials. Investors can access the webcast via the company’s website, where a replay will also be available for one year.
FAQ
What is the current stock price of Vaccinex (VCNX)?
What is the market cap of Vaccinex (VCNX)?
What is Vaccinex, Inc.?
Where is Vaccinex, Inc. located?
What is Vaccinex's lead drug candidate?
What is the focus of Vaccinex's research?
What clinical studies is pepinemab involved in?
What is the ActivMAb platform?
Who are Vaccinex's research partners?
What recent milestone has Vaccinex achieved?
How is Vaccinex funded?
Who leads the development team at Vaccinex?
